Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Multiple Myeloma × Safety × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1 Mesothelioma, Malignant 1 Leukemia, Myeloid, Acute 1 Advanced Breast Cancer 1

Interventions

Dexamethasone 714 Bortezomib 396 Lenalidomide 383 Cyclophosphamide 305 Melphalan 233 Calcium Dobesilate 208 daratumumab 193 pomalidomide 171 carfilzomib 154 fludarabine phosphate 109 fludarabine 107 Thalidomide 106 Peripheral Blood Stem Cell Transplantation 106 Filgrastim 100 ixazomib 79 Whole-Body Irradiation 74 Mycophenolic Acid 72 Granulocyte Colony-Stimulating Factor 72 Busulfan 71 dexamethasone acetate 69 Tacrolimus 63 Prednisone 58 Cyclosporine 58 dexamethasone 21-phosphate 57 auricularum 53 isatuximab 52 elotuzumab 51 belantamab mafodotin 51 Antilymphocyte Serum 49 Etoposide 45

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02786511 2020-01-22

Longterm Follow-up of Subjects Treated With bb2121

Celgene

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡